Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: A twenty-four month clinical trial

References 

1. Brill K, Then A, Beisiegel U, Jene A, Wünsch C, Leidenberger F. Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, on lipid metabolism in an open randomized trial. Contraception. 1996;54:291–297
   • Abstract
   • Full-Text PDF (1341 KB)
   • CrossRef
2. Akerlund M, Almström E, Högstedt S, Nabrink M. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel: their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet Gynecol Scand. 1994;73:136–143
   • MEDLINE
   • CrossRef
3. Archer DF, Maheux R, DelConte A, O’Brien FB. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG) Contraception. 1997;55:139–144
   • Abstract
   • Full-Text PDF (636 KB)
   • CrossRef
4. Larsson-Cohn U, Wallentin L, Zador G. Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel. Horm Metab Res. 1979;11:437–440
   • MEDLINE
   • CrossRef
5. Samsioe G. Comparative effects of the oral contraceptive combinations 0.150 mg desogestrel + 0.030 mg ethinyloestradiol and 0.150 mg levonorgestrel + 0.030 mg ethinyloestradiol on lipid and lipoprotein metabolism in healthy female volunteers. Contraception. 1982;25:487–502
   • Abstract
   • Full-Text PDF (707 KB)
   • CrossRef
6. WHO HRP Task Force on Oral Contraceptives . A randomized double-blind study of the effects of two low-dose combined oral contraceptives on biochemical aspects: report from a seven-centred study. WHO Special Programme of Research, Development and Research Training in Human Reproduction. Task force on Oral Contraceptives Contraception. 1985;32:223–236
   • Abstract
   • Full-Text PDF (815 KB)
   • CrossRef
7. Coata G, Ventura F, Lombardini R, Ciuffetti G, Cosmi EV, Di Renzo GC. Effect of low-dose oral triphasic contraceptives on blood viscosity, coagulation and lipid metabolism. Contraception. 1995;52:151–157
   • Abstract
   • Full-Text PDF (728 KB)
   • CrossRef
8. Teichmann A. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Int J Fertil Menopausal Stud. 1995;40(suppl 2):98–104
9. Burkmann RT, Robinson JC, Kruszon-Moran D, Kimball AW, Kwiterovich P, Burford RG. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstet Gynecol. 1988;71:33–38
   • MEDLINE
10. Powell MG, Hedlin AM, Cerskus I, Kakis G, Prudham D, Rosenrot P. Effects of oral contraceptives on lipoprotein lipids: a prospective study. Obstet Gynecol. 1984;63:764–770
    • MEDLINE
11. Corson SL. Efficacy and clinical profile of a new oral contraceptive containing norgestimate: US clinical trials. Acta Obstet Gynecol Scand Suppl. 1990;152:25–31
    • MEDLINE
12. Kakis G, Powell M, Marshall A, Woutersz TB, Steiner G. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Int J Fertil Menopausal Stud. 1994;39:283–291
    • MEDLINE
13. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses’ Health Study. Am J Obstet Gynecol. 1990;163(1 Pt 2):285–291
    • Abstract
    • Full-Text PDF (712 KB)
14. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ oral contraception study. BMJ. 1989;298:165–168
    • MEDLINE
    • CrossRef